[The Dynamic Monitoring of Benefit/Risk Balance in the System of Pharmacological Control].
«The thalidomide tragedy» served as a push for developing modern system of pharmacological control forcing many countries to revise actual practice of medications' licensing. The pharmacological control is a sector of science and business being engaged in detection, evaluation, interpretation and prevention of side-effects of medications and other problems related to pharmaceuticals. The predestination of specialists of pharmacological control is in increasing safety of patients and amelioration of caring, ensuring public health and safety in case of application of various medications. Their predestination also includes promoting understanding, awareness and effective communications related to health care specialists and community. The article considers regulations of pharmacological control at the territory of the Russian Federation and also main accounting of producer and its periodicity needed for implementation of evaluation of benefits/risks for pharmaceuticals. Nowadays, owing to continuous and strict implementation of all activities in the Russian Federation and the Eurasian Economic Union described in this review, a strictly regulated system of pharmacological control is functioning. This system enables all interested subjects of turnover of pharmaceuticals (manufacturers and holders of registration certification, medical organizations and medical professionals, patients and regulating agencies).